ValuEngine lowered shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) from a sell rating to a strong sell rating in a report issued on Tuesday morning.
Aptevo Therapeutics (APVO) traded up 2.27% on Tuesday, hitting $1.80. 55,602 shares of the stock were exchanged. The company has a 50-day moving average of $1.99 and a 200 day moving average of $2.01. Aptevo Therapeutics has a 12 month low of $1.68 and a 12 month high of $3.64. The firm’s market cap is $38.16 million.
Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings data on Friday, May 12th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.23. The firm had revenue of $7.41 million during the quarter. Aptevo Therapeutics had a negative net margin of 305.99% and a negative return on equity of 56.35%. Equities research analysts expect that Aptevo Therapeutics will post ($2.26) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://stocknewstimes.com/2017/08/04/valuengine-lowers-aptevo-therapeutics-inc-nasdaqapvo-to-strong-sell.html.
A hedge fund recently raised its stake in Aptevo Therapeutics stock. Spark Investment Management LLC raised its position in Aptevo Therapeutics Inc. (NASDAQ:APVO) by 167.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 61,500 shares of the biotechnology company’s stock after buying an additional 38,500 shares during the period. Spark Investment Management LLC owned 0.29% of Aptevo Therapeutics worth $127,000 at the end of the most recent quarter. Institutional investors and hedge funds own 41.86% of the company’s stock.
About Aptevo Therapeutics
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aptevo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
